XIAP and neoplasm: In fact, recent studies show that inhibitors of IAP proteins including XIAP can augment both prophylactic and therapeutic antitumor vaccines in vivo[56] and targeting XIAP degradation enhances granzyme and NK cell-induced cytolysis of target tumor cells [57].